The antibody domain controlling reactions between platelet membranes and drug-dependent (dd) antibodies from patients with thrombocytopenia induced by cinchona alkaloids was studied using F(ab')2, Fab, and Fc fragments made from purified ddIgG. By direct binding radioimmunoassay (RIA) measurements, 20,000 to 50,000 antibody molecules bound per platelet equivalent of purified platelet membranes at apparent saturation with three different antibodies. F(ab'`) and Fab fragments bound to platelet membranes drug dependently but Fc fragments did not.
ntroduction Drug-induced antibodies that cause thrombocytopenia attach to platelet membranes in a high affinity reaction only when the sensitizing drug or one of its analogues is present in solution (1) (2) (3) (4) . In vitro binding of the antibody to platelet membranes has been measured over drug concentrations of lo-7 to> 10-2 M (2-4), while in vivo binding, as evidenced by decreases in circulating platelets, has been observed at drug concentrations as low as l0-9 M (5, 6) . The highest concentrations of drug used in antibody binding experiments, 10-310-18 M, supported maximal attachment ofantibody to platelets even when antibody concentrations were in the range of I0-8-10-9 M (3, 4) and cell membrane receptors were in the range of 10-8 M. Thus, under conditions of a fixed ratio of antibody concentration to platelet concentration, antibody binding to platelets in vitro is saturable with increasing concentrations of free drug and remains so as drug is increased to at least 105-fold greater than the concentration of either antibody or platelet binding sites.
A preliminary report of this work was presented at the 26th Annual Meeting of the American Society for Hematology, December 1984. Since haptenic inhibition of antibody attachment to platelets does not occur, the assumption that simple haptenic conjugation of the drug or a metabolite with the platelet surface creates a site for antibody attachment cannot be defended. Moreover, platelets exposed to drug and washed once in the absence of drug-dependent (dd)' antibody are incapable of supporting antibody attachment (3, 4) . To be consistent with these observations, it was proposed that antibody binds drug, resulting in an immune complex that can be adsorbed by platelet membrane binding sites (2, 3) . Although antigen-antibody complexes generally are considered to be adsorbed by cell membrane Fc receptors through the activated Fc domain of the antibody, the platelet surface component that interacts with drug antibodies has been demonstrated to be the glycoprotein I complex, which has a reduced apparent molecular weight (MJ) of 150,000 (7) .
This receptor differs significantly from the platelet Fc receptors thus far described which, when reduced, have Mrs of 40,000 (8) and 50,000 (9) . Moreover, if Fc receptors were involved, drug antibodies would be expected to bind to more than one cell type, but anti-platelet drug antibodies are exclusively specific for platelets (1, 2, 6, 10) . Additionally, drug antibodies that react with granulocytes or erythrocytes show no binding to platelets (6, 10) .
These observations indicate that the cell membrane binding site for drug antibodies contributes some ofthe specificity to the overall interaction. Since adsorption ofa drug-antibody complex via the Fc domain does not appear to occur, one might expect dd antibodies to attach via the Fab domain. However, two groups of investigators have described unsuccessful attempts to demonstrate drug-mediated binding of F(ab')2 fragments prepared from dd-IgG (1 1, 12) . Nevertheless, there is a possibility that the anti-IgG used in these experiments may not have reacted with F(ab')2; experiments to document the reactivity of the anti-IgG used were not mentioned. On the other hand, Staphylococcus aureus protein A has been used successfully to detect dd-IgG on platelet surfaces (10, (12) (13) (14) ; hence the Fc domain of the ddIgG is accessible after binding. Thus, either the Fab domain is primarily involved in binding dd-IgG to the platelet surface or Fc-mediated binding does not interfere with protein A binding to the Fc region. That the latter may be possible is evident from observations on Fc receptor binding of IgG complexed to protein A (15) .
We have generated data indicating that the Fab domain of the dd-IgG rather than the Fc domain supports attachment of the antibodies to cell membranes. The high affinity antibodydrug-platelet ternary complex appears to involve cooperative interaction among the three reactants, in that the affinity between any two of the reactants in the absence of the third is too low to be measured by techniques that have been applied to date.
Methods
Patients. The antibodies studied were from three patients who developed severe thrombocytopenia while taking either quinine or quinidine therapeutically. dd antibody binding in each serum was initially quantitated by complement fixation assays as reported previously (2) .
Production ofpurified IgG and fragments. 10 removed by adsorption to a protein A-Sepharose column. The purity of all these fiagments was determined by analytical SDS-PAGE (e.g., Fig. 7) .
Platelet membrane preparation. Platelets were obtained from normal donors by platelet apheresis using citrate anticoagulant. EDTA was added to the platelet-rich plasma to a final concentration of 5.0 mM and platelets were washed three times in phosphate-buffered saline (PBS), 5.0 mM EDTA. To prepare membranes, glycerol-loaded platelets were lysed by hyptonic shock and the membrane fragments were separated from intact platelets, cellular debris, and organelles by centrifugation through a discontinuous sucrose density gradient (20). The membrane preparation sedimented to the interface between the 0.25 M and 27% sucrose solutions. The material that sedimented through the 27% sucrose cushion was resuspended in 0.25 M sucrose and subjected to a second differential centrifugation. This procedure resulted in a greater recovery ofthe platelet drug-antibody receptor as has been previously described (7) . Protein concentration in platelet membrane suspensions was determined using fluorescence measurements after derivitization with o-phthalaldehyde (21) . Membranes were washed and resuspended in PBS and stored at -70'C. Each batch ofplatelet membranes was evaluated using radioimmunoassay (RIA) for PlAI antigen (22) . Specifically, glycoprotein IlIa was purified by differential detergent extraction (23) and gel filtration on Sephacryl S-300 (24) and radiolabeled using a chloramine-T method (25) . The immunoassay consisted of mixing this radiolabeled antigen with anti-PI" at molar equivalence and precipitating the resulting antigen-antibody complexes with formalin-fixed S. aureus to obtain the maximum value for percent binding in Fig. 1 . Curves were then obtained using varying amounts of either intact platelets or platelet membranes to compete with the labeled glycoprotein for anti-PI"', as shown in Fig.   1 . By comparing the number ofintact platelets with the amount ofpurified platelet membranes required to inhibit binding by 50%, a specific amount of platelet membrane protein could be converted to an equivalence of whole platelets based upon PIl" antigen content.
dd binding to platelet membranes. All fragments of each antibody were assayed using a single preparation ofplatelet membranes to minimize the variation in receptor concentration that may arise from comparisons among individual platelet preparations. Membrane ml. This mixture was incubated for 30 min at room temperature, centrifuged at 12,000 g for 5 min in a Beckman model 12 microftge, and the pellet was washed three times in saline with or without the appropriate drug. An acid eluate was prepared from the final washed pellet by resuspension in 266 Ml ofPBS, 0.5% BSA, plus 133 MLI of 10 mM phosphoric acid, to give a final pH of 3.1. This mixture was incubated at room temperature for 10 min and again centrifuged at 12,000 g for 10 min, after which 52 Ml of 2.5 M Tris, pH 10.0, was added to a 332-Ml aliquot of the supernatant to bring the pH to -7.0.
A "sandwich" RIA was used to measure eluted IgG (26) . Various dilutions of the eluates in 40-Ml aliquots were added to 100 Ml of RIA buffer (10 mM Tris HCI, 0.5% BSA, pH 8.3) and then loaded onto wells ofpolystyrene microtiter plates that had been precoated with anti-human IgG (affinity-purified goat anti-human IgG, heavy chain-specific; Kirkegaard & Perry, Gaithersburg, MD). After incubation for 2-18 h at room temperature, the plates were washed with RIA buffer, and a radioiodinated second antibody (antihuman IgG from the same lot as the material with which the plate was originally coated) diluted in RIA buffer to contain 50,000-100,000 cpm/100 td was added to each well. This labeled antibody was allowed to bind for 2 h at room temperature. The plates were then washed three times, and individual wells were cut out and counted in a gamma counter. The quantitative results were determined from standard curves on control IgG, F(ab')2, Fab, or Fc that were run with each determination. A typical set of standard curves is shown in Fig. 2 . The raw data was analyzed by a modified logit transformation, where each curve was subjected to linear regression analysis. Standard curves spanning the range of 0.05-125 ng ofIgG or its fragments were used to quantitate the total acid eluted immunoreactive material.
Quantitative complementfixation. Briefly, the dd-IgG was incubated with 8 X I07 platelets in the presence of 10 U ofguinea pig complement with or without appropriate drug. After 30 min of incubation at 370C the reaction was stopped, an aliquot ofthe suspension removed, and the complement activity remaining in the aliquot was quantitated using an indicator system ofhemolysin-sensitized sheep red blood cells. The assay procedure was identical to that described previously (27) for direct determination ofIgG binding as well as for evaluation ofcompetitive binding of non-complement-fixing IgG allo-antibodies in the presence of complement-fixing antibodies of the same specificity.
When competitive experiments were performed, the order ofaddition ofreagents to the reaction mixture was as follows: veronal-buffered saline; platelets; IgG; IgG fragments [F(ab`), Fab 
Results
Binding ofdd-IgG and ddfragments to platelet membranes. Fig.   3 shows the dose-dependent response of dd-IgG binding to washed platelet membranes using purified total serum IgG from three different patients, one having quinine-dependent purpura, a second having quinidine-dependent purpura, and a third who showed sensitivity to both drugs. The amounts of purified IgG available limited evaluation to the values shown, which suggests, but may not assure, saturation in each case.
When IgG and its fiagments were incubated with platelet membranes, binding occurred with IgG, Fab, and F(ab')2 only in the presence of the drug. Using equimolar amounts of IgG and its fragments, the amounts of each preparation that were eluted after binding to a standard sample of platelet membrane are shown in Fig. 4 a. IgG showed the maximum, F(ab')2 intermediate, and Fab the least binding. In contrast, binding of the Fc fragment was not dd, since the same amount bound whether 3 4 or not the appropriate drug was present, as shown in Fig. 4 The washed membranes were resuspended in 2.0 ml PBS, 0.5% BSA. The pH was then adjusted to 2.8 with dilute phosphoric acid, and the membranes, after incubation for 10 min in these acid conditions, were removed by centrifugation. The pH ofthe supernatant was immediately adjusted to 7.0 with dilute NaOH. This acid eluate contained 1.4 X 10-8 mol ofIgG by RIA, ofwhich 95% was dd. This percentage was determined by quantitating the maximum amount of IgG bound when an aliquot ofeluate was exposed to an excess of platelet membrane in the presence of 1.0 mM quinidine.
For further purification, the eluate was then applied to a protein ASepharose column equilibrated in PBS, and the adsorbed dd-IgG was eluted in 1.0 M acetic acid, pH 2.8, pooled, and neutralized. Aliquots of 10 Ag dd-IgG were radioiodinated with '25I using chloramine-T (25) .
Acid elution and electrophoresis ofplatelet-bound radiolabeled F(ab')2. F(ab')2 was prepared by pepsin digestion of IgG separated from serum of patient III and labeled with 1251I by the chloramine-T method (25). 1.5 X I09 platelets were mixed with sufficient 1251I-F(ab')2 to saturate binding sites, assuming F(ab')2 attached to platelets in the same quantities as dd-IgG. Quinidine gluconate was added to achieve a final drug concentration of 1 mM. Drug was omitted in the control mixture. After incubation at room temperature for 24 h, platelets were pelleted and supernatants removed. Pellets were washed twice in 0.85% saline with or without 1 mM drug, as in the original mixtures, and final pellets were resuspended in 0.375 cm-3 0.85% saline. The pH was adjusted to 2.8 with 0.1 N HC1, and after 10 min platelets were pelleted and supernatants recovered and neutralized to pH 7 with 0.01 N NaOH. Dilutions of the radiolabeled F(ab')2 starting material and of the different eluates were electrophoresed, nonreduced, on a 7% SDS-polyacrylamide gel, which was subsequently stained with Coomassie Brilliant Blue, soaked in autofluor (National Diagnostics, Inc., Somerville, NJ), dried, and autoradiographed. Several nonradioactive IgG fragment preparations and Inhibition of dd-IgG-mediated complement fixation. The ability of Fab and F(ab')2 fiagments to interact with the dd-IgG binding sites was also observed using complement fixation as the measure of IgG binding. As shown in Fig. 6 , both F(ab')2 and Fab significantly inhibited complement fixation by the parent IgG. A summary of the relative efficiency of inhibition of these IgGs by their respective fragments is shown in Table I . The molar excess of fiagments required to produce 50% inhibition of maximum complement fixation by IgG, from which they were derived, is 1.6-3-fold for the F(ab')2 fragments and 44-75-fold for the Fab fragments.
SDS-PAGE of eluted radiolabeled dd-F(ab')2. Eluates of platelet membranes exposed to F(ab')2 in the presence or absence ofdrug were electropheresed and autoradiographed as described in Methods.
As shown in Fig. 7 , the eluate prepared with quinidine ( Fig.   7 , lanes 7 and 8) contained a high concentration of F(ab')2, while the eluate prepared without drug (Fig. 7 , lane 9) had only barely detectable F(ab')2. The dd eluate also contained traces of material of -50,000 mol wt that contaminated the F(ab')2 preparation (Fig. 7 , lanes 5 and 6). This contaminant is most likely Fab' fragment derived from the pepsin treatment of IgG that was not removed by the S. aureus protein A and anti-Fc columns. The contaminant was relatively low in concentration, as can be seen by its disappearance with dilution.
Discussion
In an attempt to resolve the conflicting data concerning antibody domain involved in dd-antibody binding, our studies were done ib')2, dd-Fab, and dd-Fc fragments relative to intact ddbimolecular reactions is difficult because of the above-cited inmeasured; two methods of determining inhibition of dication that these reactions are of low relative affinity. Prelimding by dd-IgG fragments were used; and membraneinary data on such binding in an erythrocyte dd-antibody system 51I-dd-F(ab')2 was evaluated by qualitative SDS-PAGE.
indicates the types ofapproaches that will be necessary to define of these assays consistently demonstrated that only the the dd-antibody system involving platelets (30) .
Fab domain of the IgG is responsible for dd-IgG binding, and that the affinity of dd binding increases in the order of Fab, F(ab')2, and IgG. Additionally, the observed differences in apparent affinity of the monomeric and dimeric fragments, as evaluated by differences in their ability to compete for dd-IgG binding strongly suggest that the Fab-mediated binding of ddIgG to the platelet surface is divalent at the optimal drug concentrations used.
As shown in Fig. 5 
